Cyberonics balks at ANS advance
This article was originally published in The Gray Sheet
Executive Summary
VNS Therapy manufacturer says it is "not interested in any combination" in response to ANS' purchase of 14.8% of Cyberonics' common stock on Aug. 12-13 and subsequent entreaty to enter merger talks. ANS' investment came directly after Cyberonics' share price dropped 40% on the news of FDA's rejection of its VNS Therapy PMA for depression (1"The Gray Sheet" Aug. 16, 2004, p. 5). Perhaps to Cyberonics' disdain, much of the decline was regained upon ANS' proposed merger announcement: the issue rose 31% to close the week at $19.58. ANS is the third firm to publicly court Cyberonics, following discarded bids from Medtronic and St. Jude in 2000 and 1996, respectively...
You may also be interested in...
Cyberonics Rejects Second ANS Bid, Considers Offer Beneath Self-Appraisal
Advanced Neuromodulation Systems likely would need to up the ante to sway Cyberonics shareholders to accept a takeover bid after CEO Skip Cummins' rejection of initial offers as too low
Epilepsy Sales Efforts Redouble After FDA Letter Sends Blues To Cyberonics
Cyberonics will continue to screen 400 applicants for sales positions at its Houston office while working quickly to resolve the "not-approvable" status of its VNS Therapy depression claim
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”